Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | PPARD | Q03181 | 7/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826723 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL15228378 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL28984127 | 0.94 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL26978723 | 0.92 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL17749212 | 0.92 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL31380118 | 0.92 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL26693089 | 0.92 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL31242631 | 0.92 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL7103373 | 0.89 | TSHR (0.60) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL1532024 | 0.86 | ALDH1A1 (0.58) | ALDH1A1TSHRLMNANFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3921327-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3700578-A1 | COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION | MediBeacon Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| WO-2020163642-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-2300514-A1 | A METHOD OF SYNTHESIZING A SUBSTANTIALLY MONODISPERSED MIXTURE OF OLIGOMERS | Biocon Limited (IN) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010007626-A1 | A METHOD OF SYNTHESIZING A SUBSTANTIALLY MONODISPERSED MIXTURE OF OLIGOMERS | BIOCON LIMITED (IN) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | ALDH1A1 822/4885TSHR 772/4885LMNA 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.